Jinzi Jason Wu, Ph.D.

New Capabilities

As of September 2026: Leading ASC50 development and pipeline strategy

Psoriasis patients with moderate-to-severe disease have long relied on injected antibody drugs. Ascletis, a Hong Kong-listed biotech, says its experimental pill hits the same target without a needle. In a 28-day Phase I study of mild-to-moderate plaque psoriasis, once-daily 200 mg of ASC50 cut psoriasis area and severity index (PASI) scores by 48.9% over placebo.

Updated Sep 29